Pre-Tax Income: Company's earnings or loss before taxes on income have been accounted for.
Iovance Biotherapeutics, Inc. (IOVA) had Pre-Tax Income of $-109.67M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$59.95M |
|
$-111.66M |
|
$56.66M |
|
$3.29M |
|
$173.73M |
|
$-113.77M |
|
$4.10M |
|
|
Pre-Tax Income |
$-109.67M |
$-109.67M |
|
$-111.66M |
|
$-111.66M |
|
$-111.66M |
|
$-111.66M |
|
$-113.77M |
|
$-103.84M |
|
334.51M |
|
334.51M |
|
$-0.33 |
|
$-0.33 |
|
| Balance Sheet Financials | |
$422.50M |
|
$122.47M |
|
$484.94M |
|
$907.44M |
|
$129.16M |
|
-- |
|
$79.79M |
|
$208.95M |
|
$698.49M |
|
$402.24M |
|
$698.49M |
|
341.92M |
|
| Cash Flow Statement Financials | |
$-171.14M |
|
$29.71M |
|
$156.54M |
|
$122.05M |
|
$138.41M |
|
$16.36M |
|
$37.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.27 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
5.48% |
|
-189.78% |
|
-189.78% |
|
-- |
|
-182.93% |
|
-186.25% |
|
$-184.81M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
1.14 |
|
1.00 |
|
89.98 |
|
-15.99% |
|
-27.76% |
|
-12.30% |
|
-15.99% |
|
$2.04 |
|
$-0.55 |
|
$-0.51 |
|